Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL27304475 | 0.98 | ADORA2A (0.55) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| Ethane SCHEMBL27889933 | 0.98 | PI4KA (0.54) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| Hydrazine SCHEMBL27389392 | 0.96 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| Hexane SCHEMBL27871520 | 0.88 | SMN1; SMN2 (0.58) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| Chlorobenzene SCHEMBL27871510 | 0.88 | PDE4A (0.55) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| Heptane SCHEMBL27871641 | 0.87 | SMN1; SMN2 (0.60) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| Hydrochloric Acid SCHEMBL14830202 | 0.85 | ADORA2A (0.44) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| Trifluoromethanesulfonic Acid SCHEMBL28146709 | 0.81 | PKM (0.43) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL24183832 | 0.80 | TLR7 (0.43) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL3075421 | 0.75 | ADORA2A (0.75) | PI4KAPI4K2BPI4K2API4KBPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 799 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727445-A1 | INFECTION-SENSING MEDICAL SYSTEMS AND METHODS | Bard Access Systems, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| WO-2025149628-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | WO | claimed |
| WO-2025019242-A1 | INFECTION-SENSING MEDICAL SYSTEMS AND METHODS | BARD ACCESS SYSTEMS, INC. (US) | 2025-01-23 | — | — | WO | claimed |
| EP-4275042-A1 | DETECTION OF RESPIRATORY TRACT INFECTIONS (RTIS) | Nanose Medical Ltd (IL) | 2023-11-15 | — | — | EP | claimed |
| US-20220378797-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2022-12-01 | — | — | US | claimed |
| WO-2022149132-A1 | DETECTION OF RESPIRATORY TRACT INFECTIONS (RTIS) | NANOSE MEDICAL LTD (IL) | 2022-07-14 | — | — | WO | claimed |
| US-20220104465-A1 | TREATMENT RESERVOIRS AND SYSTEMS FOR CONTROLLED RELEASE OF A TREATMENT COMPOUND IN AN AQUATIC ENVIRONMENT | W. L. GORE & ASSOCIATES, INC. | 2022-04-07 | — | — | US | claimed |
| EP-3923711-A1 | TREATMENT RESERVOIRS AND SYSTEMS FOR CONTROLLED RELEASE OF A TREATMENT COMPOUND IN AN AQUATIC ENVIRONMENT | W. L. Gore & Associates, Inc. (US) | 2021-12-22 | — | — | EP | claimed |
| CN-113766830-A | Treatment reservoir and system for controlled release of treatment compounds in aquatic environments | W.L.戈尔及同仁股份有限公司 | 2021-12-07 | — | — | CN | claimed |
| WO-2020168095-A1 | TREATMENT RESERVOIRS AND SYSTEMS FOR CONTROLLED RELEASE OF A TREATMENT COMPOUND IN AN AQUATIC ENVIRONMENT | W. L. GORE & ASSOCIATES, INC. (US) | 2020-08-20 | — | — | WO | claimed |
| EP-2190434-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2010-06-02 | — | — | EP | claimed |
| EP-1532149-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-12-30 | — | — | EP | claimed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| WO-2009024542-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-26 | — | — | WO | claimed |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-16 | — | — | US | claimed |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-09 | — | — | US | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | claimed |
| EP-0337308-B1 | 2-Pyridylmethylthio derivatives and antiulcer agents | NISSHIN FLOUR MILLING CO (JP) | 1994-11-30 | — | — | EP | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | PI4KA 1546/4885PI4K2B 2905/4885PI4K2A 3134/4885 |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | PI4KA 1546/4885PI4K2B 2905/4885PI4K2A 3134/4885 |
| US-20220378797-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | DPP4, DPP3, DPP7 | PI4KA 329/4885PI4K2B 711/4885PI4K2A 790/4885 |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | PI4KA 918/4885PI4K2B 1600/4885PI4K2A 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.